Spore

Market position

Spore.Bio positions itself as offering the first direct, culture-free method for industrial microbial testing, contrasting with petri-dish culture and interim approaches such as ATP testing and solid-phase cytometry. It acquired Greentropism, described as a competitor in spectral analysis and spectroscopy-based quality control. Investors describe it as applying photonics and AI to reach detection levels comparable to traditional methods in real time.

Differentiation claimed in the sources rests on eliminating culture, enrichment and dyes, enabling on-site testing on the factory floor rather than off-site lab shipment, and compressing multi-day turnaround into minutes (under 10 minutes for the TMSI platform). Additional stated moats are the proprietary deep learning model, access to the Pasteur Institute biobank for training data, and IP acquired with Greentropism.

Technology

The platform combines optics/photonics with deep learning. Light at specific wavelengths (UV-infrared) is projected at a sample and its spectral signature is recorded, then classified by a deep learning model trained on contaminated and uncontaminated data. The company brands this as TMSI, Transformer-based Multimodal Spectral Imaging, and describes it as reagent-free and culture-free, capable of detecting, quantifying and identifying living microorganisms in under 10 minutes. The trained model is described as the company's principal asset; a partnership with the Pasteur Institute provides access to its bacteria biobank, and the acquisition of Greentropism added expertise and IP in spectral analysis, chemometrics and spectroscopy-based quality control.

Go-to-market

The company began with proofs of concept with industrial partners in 2023, converted to paid contracts, and shipped its first prototypes into factories in May 2024, iterating with hands-on industrial feedback before broader commercialisation. It reports signed contracts covering up to 200 factories and an oversubscribed waitlist for prototypes, and stated plans to deploy dozens of systems and prepare for commercialisation before the end of 2025. Academic credibility is supported by the Pasteur Institute partnership.

Manufacturers subject to microbiological quality control, initially food and beverage producers, and extending to cosmetics companies (which face pressure to remove preservatives), pharmaceutical manufacturers, and producers of advanced therapies such as gene and cell therapies whose products can have shelf lives as short as seven days. Water and environmental testing is also listed as an application field.

Geography

Headquartered in Paris, France, with a team described as spanning 18 nationalities. Investor materials referenced plans to deploy hardware and software systems globally, and the CEO's background covers factories worldwide, but specific country deployments are not detailed in the sources.

History

Founded in 2023, the company signed its first proof of concept in March 2023 and, per its own timeline, completed a pre-seed round in May 2023 followed by an €8 million round closed in September 2023; press coverage dates the €8 million (about $8.3 million) pre-seed led by LocalGlobe to December 2023, with public announcement of the company's emergence from stealth in February 2024. A first commercial contract came in October 2023 and a first validation study in December 2023. First prototypes shipped to factories in May 2024. A $23 million (€22 million) Series A led by Singular was announced in February 2025, alongside the acquisition of Greentropism and a partnership with the Pasteur Institute. In January 2026 the company was named a recipient of the Google.org AI for Science fund and hired Dr Michael J. Miller as VP of Scientific and Regulatory Affairs, with a TMSI platform launch dated March 2026 on its timeline.

Risks & controversies

Sources contain inconsistent funding data: the pre-seed is variously dated May 2023, September 2023 and December 2023 and sized at €8 million, €7.9 million or $9 million, and total funding is reported as €29.9 million, $32.0 million or more than $35 million; one aggregator also lists Series A investors (Project A Ventures, Christian Reber, Nicolas Brusson, Iris Capital, Partech, Entrepreneur First) not corroborated by primary press coverage. Third-party commentary notes that regulatory acceptance of non-culture rapid methods and demonstrated false-positive/negative performance in real deployments remain determinants of commercial success. Headcount figures for early 2025 differ between sources (25 vs 30). No litigation or controversy is reported in the sources.